# CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)

> **NCT03559660** · — · NO_LONGER_AVAILABLE · sponsor: **UCB Biopharma SRL**

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Certolizumab Pegol

## Key facts

- **NCT ID:** NCT03559660
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03559660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03559660, "CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03559660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*